About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Endocrinology
General Surgery
Hematology
Nephrology
Neurosurgery
Oncology
Oral Maxillofacial
Orthopaedics
Pediatrics
Plastic Surgery
Podiatry
Primary Care
Pulmonology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, and How to Salvage Therapy
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Sundar Jagannath
October 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
10:37
Amgen Oncology
Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse
Feat.
J. Abbas
Featured Video
10:37
Amgen Oncology
Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse
Feat.
J. Abbas
Related Content
AUTOPLAY
ON
Moffitt Cancer Center
16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Sat, Jan 18, 2020
The University of Kansas Cancer Center
KU ASH 2019 Review: Current Updates in Hematologic Diseases
Sat, Jan 18, 2020
UChicago Medicine Comprehensive Cancer Center
UChicago Annual Updates from ASH 2019
Fri, Feb 28, 2020
Indy Hematology Review
17th Indy Hematology Review
Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Fri, Feb 7, 2020
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...
Feat.
M. Dimopoulos
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases
MM - Overview of Trials Presented at ASH 2018
Feat.
A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference
Evolution of Myeloma Induction Regimens
Feat.
S. Holstein
19:49
Gareth J Morgan
Contemporary Design of MM Treatment: Developing New Therapeutic Endpoint...
17:03
Ajai Chari
Diagnosing Smoldering Multiple Myeloma
05:05
Indy Hematology Review
Risk of Progression of Smoldering Myeloma to Active Multiple Myeloma
Feat.
K. Anderson
10:17
Amgen Oncology
Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study
Feat.
H. Kaya
09:49
Nina Shah
Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...
06:12
Indy Hematology Review
Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...
Feat.
K. Anderson
19:41
Peter Voorhees
Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...
15:02
Krina Patel
Clinical Trials in Myeloma in 2018
15:11
Ajay Nooka
Early Relapse: Choosing Among Different Second Line Regimens in Myeloma
10:37
Amgen Oncology
Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse
Feat.
J. Abbas
13:26
Shaji Kumar
Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma
17:17
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Emerging Data on Management and Imaging of Myeloma Bone Disease
Feat.
M. Dimopoulos
17:03
Thomas Martin
Novel Clinical Trials for Smoldering Multiple Myeloma in 2018
16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study
Feat.
S. Jagannath
21:40
Natalie Callander
Smoldering Myeloma: Risk Stratification and Therapeutic Options
12:32
Indy Hematology Review
What's New in Immunotherapy and Genomics in Multiple Myeloma?
Feat.
K. Anderson
15:10
Krina Patel
Developing CAR T-cells in Multiple Myeloma